Gemcitabine–erlotinib versus gemcitabine–erlotinib–capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group

1. Irigoyen, A.
2. Gallego, J.
3. Guillén Ponce, C.
4. Vera, R.
5. Iranzo, V.
6. Ales, I.
7. Arévalo, S.
8. Pisa, A.
9. Martín, M.
10. Salud, A.
11. Falcó, E.
12. Sáenz, A.
13. Manzano Mozo, J.L.
14. Pulido, G.
15. Martínez Galán, J.
16. Pazo-Cid, R.
17. Rivera, F.
18. García García, T.
19. Serra, O.
20. Fernández Parra, E.M.
21. Hurtado, A.
22. Gómez Reina, M.J.
23. López Gomez, L.J.
24. Martínez Ortega, E.
25. Benavides, M.
26. Aranda, E.
27. Mostrar todos los/as autores/as +